Catecholamines and protein deposition in Parkinson's and Alzheimer's disease: Old medicine, new targets

Rejuvenation Research

Volumn 7, Issue 2, 2004, Pages 92-94

  Bharath, Srinivas ^a   Andersen, Julie Kay ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIPARKINSON AGENT; CATECHOLAMINE; LEVODOPA; TAU PROTEIN;

ALZHEIMER DISEASE; ATOMIC FORCE MICROSCOPY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; HUMAN; LEWY BODY; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; CATECHOLAMINES; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE;

EID: 4344715229     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/1549168041553071     Document Type: Review

References (12)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
2. Rajagopalan S, Andersen JK. Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech Ageing Dev. 2001;122:1499-1510.
3. Selkoe DJ. Neuroscience: Alzheimer's disease: genotypes, phenotype and treatments. Science 1997;275:630-631.
4. Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J Biol Chem 2002;277:42881-42890.
5. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000;1502:76-84.
6. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294:1346-1349.
7. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 2004;18:962-964.
8. Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riedere P. Neuroprotection by dopamine agonists. J Neural Transm Suppl 1994;43:183-201.
9. Fredriksson A, Plaznik A, Sundstrom E, Archer T. Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice. Pharmacol Toxicol 1994;75:36-41.
10. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K. A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci 2001;21:7226-7235.
11. Rochet JC, Conway KA, Lansbury PT Jr. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 2000;39:10619-10626.
12. Hastings TG, Zigmond MJ. Loss of dopaminergic neurons in Parkinsonism: possible role of reactive dopamine metabolites. J Neural Transm Suppl 1997;49:103-110.